Neurology Central

Epidyolex® receives marketing authorization from the EMA for seizures


GW Pharmaceuticals (CA, USA) has announced that the European Commission has approved the marketing authorization of Epidyolex® (cannabidiol) for use as an adjunctive therapy (in conjunction with clobazam) for seizures associated with Lennox–Gastaut syndrome (LGS) or Dravet syndrome in patients 2 years of age and older.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.